352770 — Clinomics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Annual income statement for Clinomics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4,101	9,820	55,426	23,083	11,408
Cost of Revenue
Gross Profit	1,451	1,790	37,413	8,238	289
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	8,570	22,074	32,499	33,858	47,248
Operating Profit	-4,469	-12,254	22,927	-10,775	-35,840
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-5,759	-13,146	24,819	-10,122	-42,431
Provision for Income Taxes
Net Income After Taxes	-5,760	-13,147	15,853	-10,234	-42,399
Minority Interest
Net Income Before Extraordinary Items
Net Income	-5,760	-13,147	15,853	-10,177	-42,257
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-5,760	-13,147	14,204	-10,177	-42,257
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-371	-714	542	-430	-1,538
Dividends per Share